Imatinib Krka D.D.

Imatinib, the active ingredient in Imatinib Krka D.D., is a tyrosine kinase inhibitor presented as a strength/form for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Krka D.D. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib acts on BCR‑ABL driven malignancies and related tyrosine‑kinase pathways. - Chronic myeloid leukemia (CML): restores normal blood cell production and reduces disease burden. - Gastrointestinal stromal tumor (GIST): blocks KIT signaling to inhibit tumor growth. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower extremities. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced cardiac output, especially in patients with pre‑existing heart disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: elevated pressure in lung arteries presenting with dyspnea.

Patients should be monitored closely for safety concerns before and during therapy. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Liver function assessment: check hepatic enzymes at baseline and periodically. - Cardiac evaluation: assess cardiac history and monitor for signs of heart failure. - Hypersensitivity avoidance: discontinue if severe allergic reactions occur. - Pregnancy and lactation counseling: discuss potential risks with a healthcare professional. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several co‑administered medicines.

Major Interactions (Avoid): - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): can raise imatinib plasma levels. - CYP3A4 strong inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Acid‑reducing agents (e.g., high‑dose PPIs): can lower absorption.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding risk; monitor INR. - Vaccines (live attenuated): consider timing to avoid reduced vaccine efficacy.